Heterocyclic compounds: lactams: clobazam (INN) and methyprylon (INN)

In 2024, heterocyclic compounds: lactams: clobazam (inn) and methyprylon (inn) trade exhibited strong growth, with global flows reaching $13,176,725 and a three-year compound annual growth rate of -0.2% (five-year: -3.0%). The all-time peak of $21,017,771 was recorded in 2018; the current level is 37% below that high-water mark.

Over the 30-year observation window (1995–2024), 62% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is steady (+1.4% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.319). The three largest exporters — Germany ($6.0M), France ($5.3M), and India ($2.4M) — collectively dominate supply flows. The leading exporter has grown at +6.8% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.133). The three largest import markets are India ($3.3M), France ($2.5M), and Brazil ($1.7M). The largest importing market sources from 6 different supplying countries.

Estimated substitution elasticity: -25.15. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is France → India at $3.0M, representing 92.4% of the importer's total demand.

The volatility score for heterocyclic compounds: lactams: clobazam (inn) and methyprylon (inn) is 10 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.